Incidence and risk of cardiac toxicities in patients with relapsed and refractory multiple myeloma treated with carfilzomib

PURPOSE: Carfilzomib has been approved for use in relapsed and refractory multiple myeloma (RRMM). Cardiac toxicities have been reported with the use of carfilzomib. We aimed to determine the overall incidence and risk of cardiac toxicities in RRMM patients treated with carfilzomib using a meta-anal...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Drug Des Devel Ther
Hlavní autoři: Zhao, Fang, Yang, Bo, Wang, Juan, Zhang, Rui, Liu, Jing, Yin, Fenglei, Xu, Weixing, He, Chunyuan
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2018
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5985801/
https://ncbi.nlm.nih.gov/pubmed/29881259
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S159818
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky